Evidence map›Paper›PMID 33283785›Full record

ArticleJournal of visualized experiments : JoVE2020

Profiling of the Human Natural Killer Cell Receptor-Ligand Repertoire.

Elena Vendrame, Julia L McKechnie, Thanmayi Ranganath, Nancy Q Zhao, Arjun Rustagi, Rosemary Vergara, Geoffrey T Ivison, Lisa M Kronstad, Laura J Simpson, Catherine A Blish

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Elena Vendrame *Department of Medicine, Stanford University School of Medicine.
Julia L McKechnie *Department of Medicine, Stanford University School of Medicine; Program in Immunology, Stanford University School of Medicine.
Thanmayi RanganathDepartment of Medicine, Stanford University School of Medicine.
Nancy Q ZhaoDepartment of Medicine, Stanford University School of Medicine; Program in Immunology, Stanford University School of Medicine.
Arjun RustagiDepartment of Medicine, Stanford University School of Medicine.
Rosemary VergaraDepartment of Medicine, Stanford University School of Medicine.
Geoffrey T IvisonDepartment of Medicine, Stanford University School of Medicine; Program in Immunology, Stanford University School of Medicine.
Lisa M KronstadDepartment of Medicine, Stanford University School of Medicine.
Laura J SimpsonDepartment of Medicine, Stanford University School of Medicine.
Catherine A BlishDepartment of Medicine, Stanford University School of Medicine; Program in Immunology, Stanford University School of Medicine; Chan-Zuckerberg BioHub; cblish@stanford.edu.
Stanford University · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
EMERGING INFECTIOUS DISEASEST32AI007502 · NIAID · STANFORD UNIVERSITY · PI Prasanna Jagannathan, DAVID A. RELMAN · 1995 to 2026
$6.8M
Targeting natural killer cells to HIV in intravenous drug usersDP1DA046089 · NIDA · STANFORD UNIVERSITY · PI BLISH, CATHERINE A · 2018 to 2022
$3.9M
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional CharacteristicsR01AI131798 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2017 to 2021
$2.1M
Spectrum Stanford Center for Clinical and Translational Research and EducationTL1TR001084 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$1.1M
Natural killer cells in Zika virus pathogenesisR21AI135287 · NIAID · STANFORD UNIVERSITY · PI BLISH, CATHERINE A · 2018 to 2019
$420k
Natural killer cell repertoire in HIV infection outcomesK08AI138640 · NIAID · STANFORD UNIVERSITY · PI VENDRAME, ELENA · 2019 to 2019
$187k
NCATS NIH HHS TL1 TR001084NIAID NIH HHS K08 AI138640NIAID NIH HHS R01 AI131798NIAID NIH HHS R21 AI135287NIAID NIH HHS T32 AI007290NIAID NIH HHS T32 AI007502NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U19 AI057229NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIDA NIH HHS DP1 DA046089
6 · The paper itself

Abstract

Natural killer (NK) cells are among the first responders to viral infections. The ability of NK cells to rapidly recognize and kill virally infected cells is regulated by their expression of germline-encoded inhibitory and activating receptors. The engagement of these receptors by their cognate ligands on target cells determines whether the intercellular interaction will result in NK cell killing. This protocol details the design and optimization of two complementary mass cytometry (CyTOF) panels. One panel was designed to phenotype NK cells based on receptor expression. The other panel was designed to interrogate expression of known ligands for NK cell receptors on several immune cell subsets. Together, these two panels allow for the profiling of the human NK cell receptor-ligand repertoire. Furthermore, this protocol also details the process by which we stain samples for CyTOF. This process has been optimized for improved reproducibility and standardization. An advantage of CyTOF is its ability to measure over 40 markers in each panel, with minimal signal overlap, allowing researchers to capture the breadth of the NK cell receptor-ligand repertoire. Palladium barcoding also reduces inter-sample variation, as well as consumption of reagents, making it easier to stain samples with each panel in parallel. Limitations of this protocol include the relatively low throughput of CyTOF and the inability to recover cells after analysis. These panels were designed for the analysis of clinical samples from patients suffering from acute and chronic viral infections, including dengue virus, human immunodeficiency virus (HIV), and influenza. However, they can be utilized in any setting to investigate the human NK cell receptor-ligand repertoire. Importantly, these methods can be applied broadly to the design and execution of future CyTOF panels.

Indexed as

AntibodiesCell LineDNAFreeze DryingHumansIntercalating AgentsKiller Cells, NaturalLigandsReceptors, Natural Killer CellReproducibility of ResultsStaining and LabelingAntibodiesDNAIntercalating AgentsLigandsReceptors, Natural Killer Cell

Identifiers

PMID33283785
PMCPMC7935321
OpenAlexW3109678175

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.